GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (STU:DPM) » Definitions » 14-Day RSI

Sumitomo Pharma Co (STU:DPM) 14-Day RSI : 48.06 (As of Dec. 14, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sumitomo Pharma Co 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-14), Sumitomo Pharma Co's 14-Day RSI is 48.06.

The industry rank for Sumitomo Pharma Co's 14-Day RSI or its related term are showing as below:

STU:DPM's 14-Day RSI is ranked better than
54.06% of 1095 companies
in the Drug Manufacturers industry
Industry Median: 48.1 vs STU:DPM: 48.06

Competitive Comparison of Sumitomo Pharma Co's 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's 14-Day RSI falls into.



Sumitomo Pharma Co  (STU:DPM) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sumitomo Pharma Co  (STU:DPM) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Sumitomo Pharma Co 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sumitomo Pharma Co Headlines